Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
OPEN Pituitary | 7 Dec 2019
EB Geer, J Sisco, DT Adelman, WH Ludlam, A Haviv, D Gelbaum, S Liu, SD Mathias and L Shi
Acromegaly patients, even those with IGF-1 values within the normal range receiving somatostatin receptor ligands (SRLs), often suffer from significant symptoms. It is not known to what extent patients' medical providers are aware of the frequency and severity of acromegaly symptoms or level of treatment satisfaction with SRLs. This study sought to examine the concordance between outcomes reported by acromegaly patients treated with long-acting SRLs and those perceived by their medical provider.
* Data courtesy of Altmetric.com